These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30919147)

  • 21. Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening.
    Berktold L; von Kaisenberg CS; Hillemanns P; Vaske B; Schmidt P
    Arch Gynecol Obstet; 2013 Mar; 287(3):413-20. PubMed ID: 23080546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
    Savvidou MD; Syngelaki A; Muhaisen M; Emelyanenko E; Nicolaides KH
    BJOG; 2012 Mar; 119(4):410-6. PubMed ID: 22324916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free β-hCG.
    Ekelund C; Wright D; Ball S; Kirkegaard I; Nørgaard P; Sørensen S; Friis-Hansen L; Jørgensen FS; Tørring N; Bech BH; Petersen OB; Tabor A
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):276-81. PubMed ID: 22807155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of maternal systemic lupus erythematosus on first-trimester combined screening for chromosomal abnormalities.
    Heinig J; Steinhard J; Schmitz R; Nofer JR; Kiesel L; Klockenbusch W
    Prenat Diagn; 2007 Jul; 27(7):600-2. PubMed ID: 17437322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of prenatal screening for fetal chromosome abnormality during the first trimester pregnancy in Guangzhou].
    Xu Z; Li B; Liao C; Sun Q; Bai X; Li D
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):632-5. PubMed ID: 25297598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
    Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
    Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
    Herraiz I; López-Jiménez EA; García-Burguillo A; Nieto O; Villar OP; Escribano D; Galindo A
    Ultrasound Obstet Gynecol; 2009 May; 33(5):518-23. PubMed ID: 19402101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
    Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH
    Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D; Abele H; Baker A; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.